Last reviewed · How we verify

NCT06073223

Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

Completed NA Last updated 17 February 2026
What this trial tests

NA trial testing Usual Care in Thyroid Cancer in 50 participants. Completed in 20 December 2025.

Timeline
18 September 2023
Primary endpoint
20 December 2025
20 December 2025

Quick facts

Lead sponsorUniversity of Michigan Rogel Cancer Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment50
Start date18 September 2023
Primary completion20 December 2025
Estimated completion20 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan Rogel Cancer Center

Who can join

Adults 18 to 80, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will include 50 patients newly diagnosed with low-risk thyroid cancer ranging from 18-80 years of age. After scheduling their surgeon visit, the investigators will enroll patients and measure their intended treatment choice, baseline awareness of the three treatment options, expected outcomes, self-efficacy, and activation. The participants will then be randomized 1:1 and deliver the CQUPLE intervention to the intervention group. The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit. The study team will repeat all measures prior to the surgical consult and after the surgical consult. The study team will record the patients' actual treatment choice after the consult.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Usual Care

Trials testing the same drug.

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

Other University of Michigan Rogel Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06073223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing